Keytruda

­
  • Keytruda

Keytruda

Facts of Keytruda 50 mg/vial ?

  • Medicine Name: Keytruda 50 mg/vial
  • Date of Approval: 04.09.2014
  • Company Name: Merck & Co., Inc.
Category:

Product Description

What are the indications and usage?

KEYTRUDA® (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor

What is DOSAGE AND ADMINISTRATION?

Administer 2 mg/kg as an intravenous infusion over 30 minutes every 3 weeks

Dilute prior to intravenous infusion

What are KEYTRUDA side effects?

The most common side effects of KEYTRUDA include: feeling tired, cough, nausea, itching, rash, decreased appetite, constipation, joint pain, diarrhoea.

How supplied/storage and handling ?

KEYTRUDA for injection (lyophilized powder): carton containing one 50 mg single-use vial (NDC 0006-3029-02).

KEYTRUDA injection (solution): carton containing one 100 mg/4 mL (25 mg/mL), single-use vial (NDC 0006-3026-02)

Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.

Country of Import: USA

Reviews

There are no reviews yet.

Be the first to review “Keytruda”